Stay updated on MRTX0902 for KRAS Mutation Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the MRTX0902 for KRAS Mutation Solid Tumors Clinical Trial page.

Latest updates to the MRTX0902 for KRAS Mutation Solid Tumors Clinical Trial page
- Check3 days agoChange DetectedThe screenshots show the same study details with no additions or deletions detected.SummaryDifference0.0%

- Check10 days agoChange DetectedThe trial record now indicates Terminated status and a new Phase 1 SOS1 inhibitor study of MRTX0902 with 64 participants, including Phase 1 dose escalation and expansion cohorts, replacing prior Phase 1/2 entries.SummaryDifference2%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedAdded Revision: v3.4.2. Removed the government funding lapse notice and Revision: v3.4.1.SummaryDifference0.4%

- Check31 days agoChange DetectedThe page now includes a government funding status notice about NIH operations. The site version has been updated to v3.4.1, replacing v3.4.0.SummaryDifference0.4%

- Check38 days agoChange DetectedThe page now includes a glossary toggle and updated QC metadata labels (Last Update Submitted that Met QC Criteria, Last Update Posted) along with the site revision (Revision: v3.4.0). The older labels/data references (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, Revision: v3.3.4) were removed.SummaryDifference0.2%

- Check52 days agoChange DetectedRevision history updated to include v3.3.4 and remove v3.3.3.SummaryDifference0.0%

Stay in the know with updates to MRTX0902 for KRAS Mutation Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MRTX0902 for KRAS Mutation Solid Tumors Clinical Trial page.